UBS Hosts Conference Call With Biogen (NASDAQ: BIIB) Executives

UBS hosted a conference call with Biogen (NASDAQ: BIIB) COO Robert Hamm and VP of Strategic Planning and Investor Relations Andrew Hirsch this morning. The call covered issues including "Tysabri PML risk and physician prescribing habits; status of the JCV assay, plans to reinvigorate Avonex sales, MS competitive landscape, Rituxan lifecycle, pipeline highlights and corporate and P&L issues."

UBS rates Biogen as Neutral and sets a 12 month price target of $63.00 for the stock.